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Abstract
To study drug-receptor interactions, new thio-derivatives of salvinorin A, an extremely potent natural
κ-opioid receptor (KOR) agonist, were synthesized. Obtained compounds were examined for
receptor binding affinity. Analogs with the same configuration at carbon atom C-2 as in natural
salvinorin A showed higher affinity to KOR than their corresponding epimers.
Salvinorin A (1) is a neoclerodane diterpenoid with a strong hallucinogenic activity. It has been
shown to have a high affinity and selectivity to kappa-opioid receptors (KOR)1. Salvinorin A
is isolated from the psychoactive plant Salvia divinorum as a major secondary metabolite, and
makes an attractive lead compound for drug development due to its strong effects on human
mood and low toxicity.
In the last three years numerous derivatives and analogs of salvinorin A were synthesized
showing a broad range of KOR affinities2. Synthesis of new analogs of salvinorin A is
important for generating new data on the structure of the receptor binding site and for possible
changing of a pharmacological profile of action from agonist to antagonist. The wealth of the
experimental data collected so far allows for structure-activity relationship conclusions
pointing out the crucial importance of the C-2 configuration. Structural modifications of
salvinorin A skeleton and functional groups in the other than C-2 positions did not provide
compounds with higher affinity. In the course of our work on the molecular mechanism of
interaction of salvinorin A to KOR we examined the effects of cysteine-substitution
mutagenesis on the binding of salvinorin A along with analogs containing free sulfhydryl group
at carbon C-23. These studies prompted us to find a convenient way to synthesize of 2-
thioanalogs of salvinorin A and B.
Recently we reported the synthesis of sulfur analog of salvinorin A, in which the oxygen atom
at the side chain at carbon atom C-2 was substituted by a sulfur atom2c. We now report the
new method of the synthesis of sulfur analogs of salvinorin A and B epimeric at the C-2
stereogenic center. In our method salvinorin B (2) is transformed to 2β-chloroderivative (3)
with 65% yield using mild condition of chlorination of alcohols with CCl4-Ph3P (Appel
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reaction). It is an improvement over previously used conditions (SOCl2/Py) which gives 3 with
only 29% yield2c. After 2 hours of refluxing of 2 with CCl4-Ph3P the only product formed was
3 with 80% conversion of starting material. The prolonged heating (6 h) moved the reaction
to completion but a small amount (14%) of the product of epimerization at carbon C-8 (4)
appeared (Scheme 1).
Epimerization at C-8 is well known in salvinorin chemistry, although it was previously
observed repeatedly in basic and once in acidic conditions2e, 2j-n ,4. The nucleophilic
substitution of the chlorine atom in 3 by sulfur-containing reagents may be achieved with
inversion or retention of configuration at C-2. Reaction of 3 with sodium hydrogen sulfide
(NaSH) in methanol and dimethylformamide produces a thiol 5, while the reaction with
potassium thioacetate in acetone2c provides sulfur analog of salvinorin A (6) (Scheme 2).
The formation of thiol 5 from 3 is accompanied with several side products. To avoid this, the
deacetylation of thioacetate 6 with NaSMe was chosen as cleaner and more effective method
of the synthesis of 5. Deacetylation with sodium thiomethoxide5a proved to be advantageous
in our case over the other known methods of hydrolysis of thioacetate group5b-f. The structure
of compound 5 was confirmed by spectroscopic analysis (NMR) and high resolution mass
spectrometry (HRMS)6 as well as by chemical re-acetylation to thioacetate 6. 1HNMR
spectrum of 5 showed the characteristic doublet of doublets of H-2 due to the coupling with
two protons at C-3. The large coupling constants for H-2 and H-3 protons of 5 (J=6 Hz and
12Hz) implied the β-orientation of H-2 and hence the desired α-configuration at C-2. The
presence of thiol group was also confirmed by characteristic color reaction with Ellman’s
reagent (DTNB).
The thioacetate 7 was obtained from triflated salvinorin B by reaction with potassium
thioacetate in acetone at −20°C7. In these conditions the nucleophilic substitution occurred
with inversion of configuration producing 2β-epimer (7) of compound 6. Deacetylation of 7
in analogous conditions8 described above for 6 yielded 2β-thiosalvinorin B (8) (Scheme 3).
Conducted NMR and HRMS analyses confirmed the structure of compounds 7 and 89. In this
case the coupling constants between H-2 and H-3 were smaller (J=2Hz and 5Hz for 7) and
corresponded well with calculated values for the dihedral angles H2α-C2-C3-H3α and H2α-
C2-C3-H3β indicating the β-configuration at C-2.
Compounds 5–8 were evaluated for affinity to κ-opioid receptor (KOR) at the NIMH-
sponsored Psychoactive Drug Screening Program at University of North Carolina at Chapel
Hill using radioligand binding assays. The assays were conducted according to the procedure
described earlier1,2o. The results are presented in Table 1.
In conclusion, we were able to obtain new sulfur analogs of salvinorin A and B with
“natural” (α) and inverted (β) configurations at carbon atom C-2. Thioanalogs with the same
configuration at C-2 as in natural salvinorin A showed higher affinity to KOR than their
corresponding epimers. Readily available 2β-chlorosalvinorin B (3) may serve as a convenient
intermediate for the synthesis of various new analogs modified at C-2 position, retaining α-
configuration of natural salvinorin A.
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thioacetate (5 mmol) were placed to dry acetone (10 mL) and stirred at −20°C under argon for 1 h.
The reaction mixture was allowed to warm up to room temperature, concentrated in vacuum, diluted
with water and extracted with chloroform. The combined organic extracts were dried (Na2SO4),
concentrated in vacuum to give semisolid product which was purified by column chromatography
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HRESIMS m/z [M+H]+ 449.1687 (calcd for C23H28O7S 448.1556).
8. General procedure for synthesis of 2-thiosalvinorin B (5) and 2-epi-2-thiosalvinorin B (8): To a stirred
solution of thioacetate (1 mmol) in methanol (10 mL) under argon at −20°C was added sodium
thiomethoxide (1 equiv. 1M solution in MeOH). The reaction mixture was stirred for 30 minutes. The
solution was then added to aqueous HC1 (0.1M, 20 mL). The aqueous solution was extracted with
CH2C12. The combined organic layers were washed with brine, dried over Na2SO4, filtered and
concentrated.
9. 2-epi-2-thiosalvinorin B (8): white solid, m.p. 161–163°C, [α]25D -160 (c 0.05, CHCl3), 1H NMR (400
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H-16); 13C NMR (125 MHz, CDCl3): δ 15.5 (C-20), 16.6 (C-19), 18.4 (C-7), 31.9 (C-3), 35.3 (C-9),
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Bikbulatov et al. Page 4
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2α-Sulfur analogs of salvinorin A
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2β-Sulfur analogs of salvinorin A
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Table 1
Binding affinity of compounds 1 and 5–8 to cloned rKOR (competitive binding in the presence of [3H]U69,593)
and hKOR mediated activation of intracellular calcium mobilization in HEK-293 cells.
Compounds Ki
a (nM) EC50
b (nM) Emax (%)
1 0.91 2.82±1.70 100
5 62 287±85 89±14
6 18.4±7.9 4.77±2.72 107±4
7 151±53 123±30 106±1
8 546±140 >2000 71±12
a
Values are means of three experiments, standard deviation is given in parentheses
b
In vitro effective concentration
Bioorg Med Chem Lett. Author manuscript; available in PMC 2008 April 15.
